Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 9/20 | 0.45 |
| ▸ | CTSG | P08311 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 4/20 | 0.41 |
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | HTR2B | P41595 | 4/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093151 | 0.98 | CMA1 (0.46) | CMA1CTSGGPR84HTR2AHTR2C | |
| SCHEMBL1093107 | 0.81 | GPR84 (0.42) | GPR84HTR2AHTR2CHTR2BCDK2 | |
| SCHEMBL1093139 | 0.81 | GPR84 (0.42) | GPR84HTR2AHTR2CHTR2BCA2 | |
| SCHEMBL4552632 | 0.80 | CMA1 (0.52) | CMA1CTSGGPR84HTR2AHTR2C | |
| SCHEMBL2309552 | 0.79 | CMA1 (0.46) | CMA1CTSGGPR84HTR2AHTR2C | |
| SCHEMBL1093195 | 0.78 | HTR2C (0.42) | GPR84HTR2AHTR2CHTR2B | |
| SCHEMBL7963410 | 0.78 | CMA1 (0.48) | CMA1CTSGGPR84HTR2AHTR2C | |
| Iodide SCHEMBL1295529 | 0.77 | CMA1 (0.45) | CMA1CTSGGPR84HTR2AHTR2C | |
| Iodide SCHEMBL5265557 | 0.77 | HTR2A (0.57) | CMA1CTSGGPR84HTR2AHTR2C | |
| SCHEMBL1856232 | 0.77 | CMA1 (0.45) | CMA1CTSGGPR84HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1249450-B1 | BENZIMIDAZOLE DERIVATIVES AS HUMAN CHYMASE INHIBITORS | TEIJIN PHARMA LTD (JP) | 2007-10-10 | — | — | EP | disclosed |
| US-7176320-B2 | Benzimidazole derivative | TEIJIN LIMITED (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20050267148-A1 | Benzimidazole derivative | TEIJIN LIMITED | 2005-12-01 | — | — | US | disclosed |
| US-20040162311-A1 | Benzimidazole derivative | TEIJIN LIMITED | 2004-08-19 | — | — | US | disclosed |
| US-20040010004-A1 | Benzimidazole derivatives | TEIJIN LIMITED (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1249450-A1 | BENZIMIDAZOLE DERIVATIVES | TEIJIN LIMITED (JP) | 2002-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162311-A1 | Benzimidazole derivative | CMA1, CBR3, CBR1 | CMA1 1/4885CTSG 486/4885GPR84 1193/4885 |
| US-20040010004-A1 | Benzimidazole derivatives | CMA1, CBR3, CBR1 | CMA1 1/4885CTSG 447/4885GPR84 1138/4885 |
| US-20050267148-A1 | Benzimidazole derivative | CMA1, SERPINB1, TPSAB1 | CMA1 1/4885CTSG 184/4885GPR84 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.